Development and validation of a gene expression tumour classifier for cancer of unknown primary
References (42)
- et al.
Epidemiology of unknown primary tumours
Eur J Cancer
(2002) - et al.
Switching benchmarks in cancer of unknown primary: from autopsy to microarray
Eur J Cancer
(2007) - et al.
Metastases of unknown primary site
Med Clin North Am
(1996) - et al.
Epidemiology of unknown primary tumours: incidence and population-based survival of 1285 patients in Southwest Netherlands, 1984-1992
Eur J Cancer
(2002) - et al.
Diagnostics and therapeutic management of cancer of unknown primary
Eur J Cancer
(2003) - et al.
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet
Oncology
(2008) - et al.
Cancer of unknown primary (CUP)
Crit Rev Oncol Hematol
(2005) - et al.
Diagnostic work-up of unknown primary: from immunohistochemistry to molecular profiling
Ann Oncol
(2012) - et al.
A quantitative reverse-transcription polymerase chain reaction assay to identify metastatic carcinoma tissue of origin
J Mol Diagn
(2006) - et al.
Cancer Statistics 2008
CA Cancer J Clin
(2008)
Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site
Cancer
Metastatic carcinomas from occult primary tumors. A study of 254 patients
Ann Surg
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients
Arch Intern Med
Neoplasms of unknown primary site: a clinicopathological study of autopsied patients
Tumori
Analysis of a diagnostic strategy for patients with suspected tumors of unknown primary
J Clin Oncol
Diagnostic strategies for unknown primary cancer
Cancer
Cancers of unknown primary
Cancer
Determining tissue of origin for metastatic cancers:meta-analysis and literature review of immunohistochemistry performance
Appl Immunohistochem Mol Morphol
Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm
Clin Cancer Res
Classification of human lung carcinomas by expression profiling reveals distinct adencarcinoma subclasses
Proc Natl Acad Sci USA
Gene expression profiles of primary breast tumours maintained in distinct metastases
Proc Natl Acad Sci USA
Cited by (36)
A review on trends in development and translation of omics signatures in cancer
2024, Computational and Structural Biotechnology JournalTranscriptomics and solid tumors: The next frontier in precision cancer medicine
2022, Seminars in Cancer BiologyCitation Excerpt :Transcriptomics holds promise as an additional tool for the accurate classification of cancer of unknown primary (CUP). Several investigators have explored gene expression profiles and revealed biomarkers indicative of the origin of the tumor in patients with CUP [52–56,120]. In one study, transcriptome analysis of 16 674 tumors corresponding to 22 tumor types revealed a 154-gene expression signature that aided the identification of tumor origin [120].
The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary<sup>✰</sup>: Molecular profiling of metastatic cancer of unknown primary
2021, Seminars in Diagnostic PathologyCitation Excerpt :Finally, such a gene expression signature is applied to the identification of tumor type in metastatic CUP (Fig. 1).35-37 The mainstay of gene expression profiling has evolved from real-time reverse transcriptase polymerase chain reaction (RT-PCR)38-46 or microarray-based assays47-56 to whole transcriptome analysis by RNA-sequencing.57-60 A few of these studies utilized fresh frozen tissue from tissue banks.47-49
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
2021, Cancer Treatment ReviewsCitation Excerpt :Several retrospective studies have attempted to assess the prediction accuracy of these tests performed on biopsy specimens from patients with CUP. Using correlation with clinicopathological features, the IHC profile or the identification of a latent primary as prediction comparator, these molecular based tissue of origin classifiers yield prediction accuracy from 60% to 92% [15,21–30]. This is corroborated by a prospective study demonstrating an 84% agreement of molecular profile with clinicopathological diagnosis [31].
Review of precision cancer medicine: Evolution of the treatment paradigm
2020, Cancer Treatment Reviews